Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti
The optimal time to initiate antiretroviral therapy in HIV-infected adults, especially in resource-poor areas, is debated. In this study of HIV-infected adults in Haiti, the investigators found that when antiretroviral therapy was initiated when the CD4 count was greater than 200 and less than 350 p...
Gespeichert in:
Veröffentlicht in: | The New England journal of medicine 2010-07, Vol.363 (3), p.257-265 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 265 |
---|---|
container_issue | 3 |
container_start_page | 257 |
container_title | The New England journal of medicine |
container_volume | 363 |
creator | Severe, Patrice Jean Juste, Marc Antoine Ambroise, Alex Eliacin, Ludger Marchand, Claudel Apollon, Sandra Edwards, Alison Bang, Heejung Nicotera, Janet Godfrey, Catherine Gulick, Roy M Johnson, Warren D Pape, Jean William Fitzgerald, Daniel W |
description | The optimal time to initiate antiretroviral therapy in HIV-infected adults, especially in resource-poor areas, is debated. In this study of HIV-infected adults in Haiti, the investigators found that when antiretroviral therapy was initiated when the CD4 count was greater than 200 and less than 350 per cubic millimeter, as compared with waiting until the CD4 count fell to 200 per cubic millimeter or less, the rate of death was decreased, as was the rate of incident tuberculosis.
Investigators found that when antiretroviral therapy was initiated when the CD4 count was greater than 200 and less than 350 per cubic millimeter, as compared with waiting until the CD4 count fell to 200 per cubic millimeter or less, the rates of death and of incident tuberculosis were decreased.
The optimal time to initiate antiretroviral therapy in adults who are infected with human immunodeficiency virus (HIV) remains uncertain. There have been no randomized trials to determine the optimal time to start antiretroviral therapy in adults who have CD4+ T-cell counts that are greater than 200 and less than 350 per cubic millimeter. Furthermore, there are few data on the optimal time to start antiretroviral therapy in persons who live in locations with limited resources, where high rates of tuberculosis, malnutrition, and coinfection with tropical diseases may alter the natural history of HIV disease and the optimal time to initiate . . . |
doi_str_mv | 10.1056/NEJMoa0910370 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3676927</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734001237</sourcerecordid><originalsourceid>FETCH-LOGICAL-c539t-c552a724c92f632f6bfb497a34a830a07c9f67b58aa14f175e9da121ea1123be3</originalsourceid><addsrcrecordid>eNp10c9vFCEUB3BiNHatHr2aiYnxNMqvgeVi0jSru6bVg9UrecOAZTMDKzCb7H8vTdfWmkgCHPjk8YWH0EuC3xHcifdfVp8vI2BFMJP4EVqQjrGWcyweowXGdNlyqdgJepbzFtdBuHqKTigWXFJMFuhyBWk8NHub8pybbwXCAGlozkLxyZYU9z7B2Fxd2wS7Q-NiatabH-0mOGuKrW6Yx5IbH5o1-OKfoycOxmxfHPdT9P3j6up83V58_bQ5P7toTcdUqWtHQVJuFHWC1dm7nisJjMOSYcDSKCdk3y0BCHdEdlYNQCixQAhlvWWn6MNt3d3cT3YwNpQaU--SnyAddASvH54Ef61_xr1mQgpFZS3w9lggxV-zzUVPPhs7jhBsnLOWjNe_ouxGvv5HbuOcQn2dFoQuMe0Erai9RSbFnJN1d1EI1jdt0g_aVP2rv_Pf6T99qeDNEUA2MLoEwfh876hSiip-76Yp62C3038u_A2T7aWn</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>612802562</pqid></control><display><type>article</type><title>Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Severe, Patrice ; Jean Juste, Marc Antoine ; Ambroise, Alex ; Eliacin, Ludger ; Marchand, Claudel ; Apollon, Sandra ; Edwards, Alison ; Bang, Heejung ; Nicotera, Janet ; Godfrey, Catherine ; Gulick, Roy M ; Johnson, Warren D ; Pape, Jean William ; Fitzgerald, Daniel W</creator><creatorcontrib>Severe, Patrice ; Jean Juste, Marc Antoine ; Ambroise, Alex ; Eliacin, Ludger ; Marchand, Claudel ; Apollon, Sandra ; Edwards, Alison ; Bang, Heejung ; Nicotera, Janet ; Godfrey, Catherine ; Gulick, Roy M ; Johnson, Warren D ; Pape, Jean William ; Fitzgerald, Daniel W</creatorcontrib><description>The optimal time to initiate antiretroviral therapy in HIV-infected adults, especially in resource-poor areas, is debated. In this study of HIV-infected adults in Haiti, the investigators found that when antiretroviral therapy was initiated when the CD4 count was greater than 200 and less than 350 per cubic millimeter, as compared with waiting until the CD4 count fell to 200 per cubic millimeter or less, the rate of death was decreased, as was the rate of incident tuberculosis.
Investigators found that when antiretroviral therapy was initiated when the CD4 count was greater than 200 and less than 350 per cubic millimeter, as compared with waiting until the CD4 count fell to 200 per cubic millimeter or less, the rates of death and of incident tuberculosis were decreased.
The optimal time to initiate antiretroviral therapy in adults who are infected with human immunodeficiency virus (HIV) remains uncertain. There have been no randomized trials to determine the optimal time to start antiretroviral therapy in adults who have CD4+ T-cell counts that are greater than 200 and less than 350 per cubic millimeter. Furthermore, there are few data on the optimal time to start antiretroviral therapy in persons who live in locations with limited resources, where high rates of tuberculosis, malnutrition, and coinfection with tropical diseases may alter the natural history of HIV disease and the optimal time to initiate . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>ISSN: 1533-4406</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa0910370</identifier><identifier>PMID: 20647201</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Waltham, MA: Massachusetts Medical Society</publisher><subject>Acquired immune deficiency syndrome ; Adult ; AIDS ; AIDS-Related Opportunistic Infections - drug therapy ; Anti-Retroviral Agents - administration & dosage ; Anti-Retroviral Agents - adverse effects ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiretroviral drugs ; Antitubercular Agents - therapeutic use ; Antiviral agents ; Biological and medical sciences ; CD4 Lymphocyte Count ; Drug Administration Schedule ; Drug therapy ; Female ; Follow-Up Studies ; General aspects ; Haiti ; HIV ; HIV Infections - drug therapy ; HIV Infections - mortality ; Human immunodeficiency virus ; Human viral diseases ; Humans ; Infectious diseases ; Kaplan-Meier Estimate ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Tropical diseases ; Tuberculosis, Pulmonary - drug therapy ; Tuberculosis, Pulmonary - epidemiology ; Tuberculosis, Pulmonary - prevention & control ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids</subject><ispartof>The New England journal of medicine, 2010-07, Vol.363 (3), p.257-265</ispartof><rights>Copyright © 2010 Massachusetts Medical Society. All rights reserved.</rights><rights>2015 INIST-CNRS</rights><rights>2010 Massachusetts Medical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c539t-c552a724c92f632f6bfb497a34a830a07c9f67b58aa14f175e9da121ea1123be3</citedby><cites>FETCH-LOGICAL-c539t-c552a724c92f632f6bfb497a34a830a07c9f67b58aa14f175e9da121ea1123be3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa0910370$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa0910370$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>230,314,776,780,881,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22999294$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20647201$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Severe, Patrice</creatorcontrib><creatorcontrib>Jean Juste, Marc Antoine</creatorcontrib><creatorcontrib>Ambroise, Alex</creatorcontrib><creatorcontrib>Eliacin, Ludger</creatorcontrib><creatorcontrib>Marchand, Claudel</creatorcontrib><creatorcontrib>Apollon, Sandra</creatorcontrib><creatorcontrib>Edwards, Alison</creatorcontrib><creatorcontrib>Bang, Heejung</creatorcontrib><creatorcontrib>Nicotera, Janet</creatorcontrib><creatorcontrib>Godfrey, Catherine</creatorcontrib><creatorcontrib>Gulick, Roy M</creatorcontrib><creatorcontrib>Johnson, Warren D</creatorcontrib><creatorcontrib>Pape, Jean William</creatorcontrib><creatorcontrib>Fitzgerald, Daniel W</creatorcontrib><title>Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>The optimal time to initiate antiretroviral therapy in HIV-infected adults, especially in resource-poor areas, is debated. In this study of HIV-infected adults in Haiti, the investigators found that when antiretroviral therapy was initiated when the CD4 count was greater than 200 and less than 350 per cubic millimeter, as compared with waiting until the CD4 count fell to 200 per cubic millimeter or less, the rate of death was decreased, as was the rate of incident tuberculosis.
Investigators found that when antiretroviral therapy was initiated when the CD4 count was greater than 200 and less than 350 per cubic millimeter, as compared with waiting until the CD4 count fell to 200 per cubic millimeter or less, the rates of death and of incident tuberculosis were decreased.
The optimal time to initiate antiretroviral therapy in adults who are infected with human immunodeficiency virus (HIV) remains uncertain. There have been no randomized trials to determine the optimal time to start antiretroviral therapy in adults who have CD4+ T-cell counts that are greater than 200 and less than 350 per cubic millimeter. Furthermore, there are few data on the optimal time to start antiretroviral therapy in persons who live in locations with limited resources, where high rates of tuberculosis, malnutrition, and coinfection with tropical diseases may alter the natural history of HIV disease and the optimal time to initiate . . .</description><subject>Acquired immune deficiency syndrome</subject><subject>Adult</subject><subject>AIDS</subject><subject>AIDS-Related Opportunistic Infections - drug therapy</subject><subject>Anti-Retroviral Agents - administration & dosage</subject><subject>Anti-Retroviral Agents - adverse effects</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiretroviral drugs</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>CD4 Lymphocyte Count</subject><subject>Drug Administration Schedule</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>General aspects</subject><subject>Haiti</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - mortality</subject><subject>Human immunodeficiency virus</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Tropical diseases</subject><subject>Tuberculosis, Pulmonary - drug therapy</subject><subject>Tuberculosis, Pulmonary - epidemiology</subject><subject>Tuberculosis, Pulmonary - prevention & control</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><issn>0028-4793</issn><issn>1533-4406</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp10c9vFCEUB3BiNHatHr2aiYnxNMqvgeVi0jSru6bVg9UrecOAZTMDKzCb7H8vTdfWmkgCHPjk8YWH0EuC3xHcifdfVp8vI2BFMJP4EVqQjrGWcyweowXGdNlyqdgJepbzFtdBuHqKTigWXFJMFuhyBWk8NHub8pybbwXCAGlozkLxyZYU9z7B2Fxd2wS7Q-NiatabH-0mOGuKrW6Yx5IbH5o1-OKfoycOxmxfHPdT9P3j6up83V58_bQ5P7toTcdUqWtHQVJuFHWC1dm7nisJjMOSYcDSKCdk3y0BCHdEdlYNQCixQAhlvWWn6MNt3d3cT3YwNpQaU--SnyAddASvH54Ef61_xr1mQgpFZS3w9lggxV-zzUVPPhs7jhBsnLOWjNe_ouxGvv5HbuOcQn2dFoQuMe0Erai9RSbFnJN1d1EI1jdt0g_aVP2rv_Pf6T99qeDNEUA2MLoEwfh876hSiip-76Yp62C3038u_A2T7aWn</recordid><startdate>20100715</startdate><enddate>20100715</enddate><creator>Severe, Patrice</creator><creator>Jean Juste, Marc Antoine</creator><creator>Ambroise, Alex</creator><creator>Eliacin, Ludger</creator><creator>Marchand, Claudel</creator><creator>Apollon, Sandra</creator><creator>Edwards, Alison</creator><creator>Bang, Heejung</creator><creator>Nicotera, Janet</creator><creator>Godfrey, Catherine</creator><creator>Gulick, Roy M</creator><creator>Johnson, Warren D</creator><creator>Pape, Jean William</creator><creator>Fitzgerald, Daniel W</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20100715</creationdate><title>Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti</title><author>Severe, Patrice ; Jean Juste, Marc Antoine ; Ambroise, Alex ; Eliacin, Ludger ; Marchand, Claudel ; Apollon, Sandra ; Edwards, Alison ; Bang, Heejung ; Nicotera, Janet ; Godfrey, Catherine ; Gulick, Roy M ; Johnson, Warren D ; Pape, Jean William ; Fitzgerald, Daniel W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c539t-c552a724c92f632f6bfb497a34a830a07c9f67b58aa14f175e9da121ea1123be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Adult</topic><topic>AIDS</topic><topic>AIDS-Related Opportunistic Infections - drug therapy</topic><topic>Anti-Retroviral Agents - administration & dosage</topic><topic>Anti-Retroviral Agents - adverse effects</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiretroviral drugs</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>CD4 Lymphocyte Count</topic><topic>Drug Administration Schedule</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>General aspects</topic><topic>Haiti</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - mortality</topic><topic>Human immunodeficiency virus</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Tropical diseases</topic><topic>Tuberculosis, Pulmonary - drug therapy</topic><topic>Tuberculosis, Pulmonary - epidemiology</topic><topic>Tuberculosis, Pulmonary - prevention & control</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Severe, Patrice</creatorcontrib><creatorcontrib>Jean Juste, Marc Antoine</creatorcontrib><creatorcontrib>Ambroise, Alex</creatorcontrib><creatorcontrib>Eliacin, Ludger</creatorcontrib><creatorcontrib>Marchand, Claudel</creatorcontrib><creatorcontrib>Apollon, Sandra</creatorcontrib><creatorcontrib>Edwards, Alison</creatorcontrib><creatorcontrib>Bang, Heejung</creatorcontrib><creatorcontrib>Nicotera, Janet</creatorcontrib><creatorcontrib>Godfrey, Catherine</creatorcontrib><creatorcontrib>Gulick, Roy M</creatorcontrib><creatorcontrib>Johnson, Warren D</creatorcontrib><creatorcontrib>Pape, Jean William</creatorcontrib><creatorcontrib>Fitzgerald, Daniel W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Severe, Patrice</au><au>Jean Juste, Marc Antoine</au><au>Ambroise, Alex</au><au>Eliacin, Ludger</au><au>Marchand, Claudel</au><au>Apollon, Sandra</au><au>Edwards, Alison</au><au>Bang, Heejung</au><au>Nicotera, Janet</au><au>Godfrey, Catherine</au><au>Gulick, Roy M</au><au>Johnson, Warren D</au><au>Pape, Jean William</au><au>Fitzgerald, Daniel W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2010-07-15</date><risdate>2010</risdate><volume>363</volume><issue>3</issue><spage>257</spage><epage>265</epage><pages>257-265</pages><issn>0028-4793</issn><issn>1533-4406</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>The optimal time to initiate antiretroviral therapy in HIV-infected adults, especially in resource-poor areas, is debated. In this study of HIV-infected adults in Haiti, the investigators found that when antiretroviral therapy was initiated when the CD4 count was greater than 200 and less than 350 per cubic millimeter, as compared with waiting until the CD4 count fell to 200 per cubic millimeter or less, the rate of death was decreased, as was the rate of incident tuberculosis.
Investigators found that when antiretroviral therapy was initiated when the CD4 count was greater than 200 and less than 350 per cubic millimeter, as compared with waiting until the CD4 count fell to 200 per cubic millimeter or less, the rates of death and of incident tuberculosis were decreased.
The optimal time to initiate antiretroviral therapy in adults who are infected with human immunodeficiency virus (HIV) remains uncertain. There have been no randomized trials to determine the optimal time to start antiretroviral therapy in adults who have CD4+ T-cell counts that are greater than 200 and less than 350 per cubic millimeter. Furthermore, there are few data on the optimal time to start antiretroviral therapy in persons who live in locations with limited resources, where high rates of tuberculosis, malnutrition, and coinfection with tropical diseases may alter the natural history of HIV disease and the optimal time to initiate . . .</abstract><cop>Waltham, MA</cop><pub>Massachusetts Medical Society</pub><pmid>20647201</pmid><doi>10.1056/NEJMoa0910370</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0028-4793 |
ispartof | The New England journal of medicine, 2010-07, Vol.363 (3), p.257-265 |
issn | 0028-4793 1533-4406 1533-4406 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3676927 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
subjects | Acquired immune deficiency syndrome Adult AIDS AIDS-Related Opportunistic Infections - drug therapy Anti-Retroviral Agents - administration & dosage Anti-Retroviral Agents - adverse effects Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretroviral drugs Antitubercular Agents - therapeutic use Antiviral agents Biological and medical sciences CD4 Lymphocyte Count Drug Administration Schedule Drug therapy Female Follow-Up Studies General aspects Haiti HIV HIV Infections - drug therapy HIV Infections - mortality Human immunodeficiency virus Human viral diseases Humans Infectious diseases Kaplan-Meier Estimate Male Medical sciences Middle Aged Pharmacology. Drug treatments Tropical diseases Tuberculosis, Pulmonary - drug therapy Tuberculosis, Pulmonary - epidemiology Tuberculosis, Pulmonary - prevention & control Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids |
title | Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T15%3A50%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20versus%20Standard%20Antiretroviral%20Therapy%20for%20HIV-Infected%20Adults%20in%20Haiti&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Severe,%20Patrice&rft.date=2010-07-15&rft.volume=363&rft.issue=3&rft.spage=257&rft.epage=265&rft.pages=257-265&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMoa0910370&rft_dat=%3Cproquest_pubme%3E734001237%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=612802562&rft_id=info:pmid/20647201&rfr_iscdi=true |